Reflex Sympathetic Dystrophy (RSD) / Complex Regional Pain Syndrome (CRPS)

2. Neurogenic Inflammation

Activated sensory nerves release neuropeptides such as:

• Substance P
• Calcitonin gene-related peptide (CGRP)

These mediators cause:

• Vasodilation and edema
• Increased vascular permeability
• Local immune cell recruitment

The result is sterile inflammation driven by the nervous system itself.

3. Autonomic Nervous System Dysregulation

A defining feature of RSD/CRPS is sympathetic nervous system dysfunction:

• Abnormal vasoconstriction or vasodilation
• Temperature asymmetry
• Color changes
• Sweating abnormalities

Sympathetic–sensory coupling develops, meaning:

• Sympathetic activity directly triggers pain
• Stress and emotional stimuli worsen symptoms

This explains the term “sympathetically maintained pain.”

4. Immune Activation & Cytokine Signaling

CRPS demonstrates features of immune dysregulation:

• Elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
• Mast cell activation
• Autoantibody-like activity against neural structures (in some patients)

Inflammatory signaling contributes to:

• Persistent pain
• Tissue trophic changes
• Central sensitization

5. Central Sensitization & Maladaptive Neuroplasticity

With time, pain processing becomes centralized:

• Spinal cord dorsal horn hyperexcitability
• Cortical reorganization in somatosensory and motor areas
• Altered pain perception and body schema

Pain becomes self-sustaining, even without ongoing peripheral injury.

6. Microvascular Dysfunction & Tissue Hypoxia

CRPS is associated with:

• Impaired endothelial function
• Capillary flow abnormalities
• Regional tissue hypoxia

These changes contribute to:

• Edema
• Skin and nail changes
• Muscle wasting
• Bone demineralization

Microvascular dysfunction further perpetuates pain and inflammation.

7. Failure of Resolution & Repair

Normally, inflammation resolves and tissue recovers.

In CRPS:

• Pro-inflammatory signaling persists
• Anti-inflammatory and repair pathways are suppressed
• Nervous system remains locked in a threat response

This results in chronic disease rather than recovery.

Clinical Manifestations

CRPS symptoms are regional and variable but often include:

• Severe burning or stabbing pain
• Allodynia and hyperalgesia
• Temperature and color changes
• Swelling and edema
• Skin, hair, and nail changes
• Muscle weakness and atrophy
• Joint stiffness
• Tremor or dystonia
• Anxiety and sleep disturbance

Symptoms may spread beyond the initial injury site over time.

Limitations of Conventional Management

Standard approaches include:

• Physical therapy
• Neuropathic pain medications
• Sympathetic nerve blocks
• Steroids (early disease)
• Neuromodulation (advanced cases)

While these therapies:

• Improve function
• Reduce pain in some patients

They do not:

• Correct underlying neuroimmune dysregulation
• Reverse central sensitization
• Restore normal autonomic signaling
• Reliably halt disease progression

Early intervention is critical, but many patients present after chronicity has developed.

Regenerative & Biologic Therapeutic Concepts

(Investigational / Adjunctive – Not FDA-approved for CRPS)

Neuroimmune Modulation (Research-Based)

Emerging strategies focus on:

• Reducing neuroinflammation
• Modulating cytokine signaling
• Calming overactive microglia and mast cells
• Supporting immune resolution pathways

The goal is interrupting the chronic pain–inflammation loop.

Platelet-Derived Biologics (PRP / PRF – Investigational)

Autologous platelet concentrates may theoretically:

• Modulate inflammatory signaling
• Support tissue repair
• Improve microvascular function
• Enhance local healing environments

Their use in CRPS is adjunctive and experimental, not curative.

Mesenchymal Stromal Cell & Exosome Research

MSC-derived therapies and exosomes are being studied for their ability to:

• Reduce inflammatory cytokine activity
• Modulate immune responses
• Support neural and vascular repair
• Improve mitochondrial function

Observed effects are largely paracrine and regulatory, not structural replacement.

Adjunctive Supportive Modalities

Often explored in comprehensive care models:

• Photobiomodulation (neural and mitochondrial support)
• Hyperbaric oxygen therapy (tissue oxygenation, microvascular support)
• Autonomic nervous system regulation
• Movement-based neural retraining
• Metabolic and micronutrient optimization

These approaches aim to support recovery capacity, not replace medical care.

Clinical Perspective

RSD / CRPS is best understood as:

• A neuroimmune-autonomic disorder
• With peripheral injury triggering central nervous system reprogramming
• Sustained by inflammation, autonomic dysfunction, and maladaptive plasticity

Effective management requires:

• Early recognition
• Multidisciplinary care
• Addressing nervous system biology, not pain alone

Summary

• CRPS is a chronic neuroinflammatory pain disorder
• Autonomic dysregulation and immune activation are central mechanisms
• Central sensitization drives persistent symptoms
• Conventional treatments are often symptomatic
• Regenerative and biologic approaches remain investigational
• Interrupting neuroimmune feedback loops is the key therapeutic challenge